{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:56:25Z","timestamp":1789588585917,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":46,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.vaccine.2021.12.028","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T18:25:43Z","timestamp":1640111143000},"page":"819-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Effectiveness of TBE vaccination in southern Germany and Latvia"],"prefix":"10.1016","volume":"40","author":[{"given":"Wilhelm","family":"Erber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3754-555X","authenticated-orcid":false,"given":"Farid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4892-3763","authenticated-orcid":false,"given":"Dace","family":"Zavadska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3242-1630","authenticated-orcid":false,"given":"Zane","family":"Freimane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Dobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merle M.","family":"B\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Jodar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.12.028_b0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1468-1331.2011.03434.x","article-title":"Tick-borne encephalitis in Latvia 1973\u20132009: epidemiology, clinical features and sequelae","volume":"19","author":"Karelis","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.vaccine.2021.12.028_b0010","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jmv.2097","article-title":"Characterization of tick-borne encephalitis virus from Latvia: evidence for co-circulation of three distinct subtypes","volume":"65","author":"Lundkvist","year":"2001","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2021.12.028_b0015","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jmv.20224","article-title":"Characterization of tick-borne encephalitis virus from Estonia","volume":"74","author":"Golovljova","year":"2004","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2021.12.028_b0020","unstructured":"Dobler G, Erber W, Br\u00f6ker M, Schmit H-J. The TBE book. 3rd ed.; 2020."},{"key":"10.1016\/j.vaccine.2021.12.028_b0025","unstructured":"EuropeanCommission. Commission Decision 2002\/253\/EC of 19 March 2002 laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119\/98\/EC of the European Parliament and of the Council. EC; 2002. In: EC, editor. Official Journal of the European Union L 262\/12012."},{"key":"10.1016\/j.vaccine.2021.12.028_b0030","doi-asserted-by":"crossref","unstructured":"Erber WSH, Jankovi\u0107 TV. TBE-epidemiology by country\u2014an overview. Chapter 12a. In: Dobler GEW, Br\u00f6ker M, Schmitt, HJ, editor. The TBE book. Singapore: Global Health Press; 2020.","DOI":"10.33442\/978-981-14-0914-1_12a"},{"key":"10.1016\/j.vaccine.2021.12.028_b0035","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4161\/hv.22766","article-title":"Recommendations for tick-borne encephalitis vaccination from the Central European Vaccination Awareness Group (CEVAG)","volume":"9","author":"Zavadska","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.12.028_b0040","doi-asserted-by":"crossref","first-page":"8769","DOI":"10.1016\/j.vaccine.2011.07.024","article-title":"Vaccines against tick-borne encephalitis: WHO position paper\u2013recommendations","volume":"29","author":"WHO","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.028_b0045","unstructured":"ECDC. Key messages about tick-borne encephalitis and tick-borne diseases; 2020. Available from: https:\/\/wwwecdceuropaeu\/en\/tick-borne-encephalitis\/facts\/key-messages."},{"key":"10.1016\/j.vaccine.2021.12.028_b0050","unstructured":"Kollaritsch H, Krasilnikov V, Holzmann H, Karganova GG, Barrett A, S\u00fcss J, et al. Background document on vaccines and vaccination against tick\u2013borne encephalitis. Geneva: WHO Strategic Advisory Group of Experts on Immunization; 2011. Available from: http:\/\/wwwwhoint\/immunization\/sage\/6_TBE_backgr_18_Mar_net_apr_2011pdf (last accessed May 2012)."},{"key":"10.1016\/j.vaccine.2021.12.028_b0055","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1016\/j.vaccine.2011.07.089","article-title":"Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme","volume":"29","author":"Loew-Baselli","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.028_b0060","unstructured":"EMEA. Guideline on clinical evaluation of vaccines. In: Agency EM, (CHMP) CoHMP, editors; 26 April 2018."},{"key":"10.1016\/j.vaccine.2021.12.028_b0065","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1016\/j.vaccine.2007.08.024","article-title":"Field effectiveness of vaccination against tick-borne encephalitis","volume":"25","author":"Heinz","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.028_b0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3201\/eid1901.120458","article-title":"Vaccination and tick-borne encephalitis, central Europe","volume":"19","author":"Heinz","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2021.12.028_b0075","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1016\/j.vaccine.2017.03.059","article-title":"Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5mL in adults","volume":"35","author":"Konior","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.028_b0080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4161\/hv.5.8.8571","article-title":"Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5 ml in adults aged 18\u201367 years","volume":"5","author":"Loew-Baselli","year":"2009","journal-title":"Human Vaccines"},{"key":"10.1016\/j.vaccine.2021.12.028_b0085","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1016\/j.vaccine.2019.03.032","article-title":"Seropersistence and booster response following vaccination with FSME-IMMUN in children, adolescents, and young adults","volume":"37","author":"Poellabauer","year":"2019","journal-title":"Vaccine"},{"issue":"Suppl 33","key":"10.1016\/j.vaccine.2021.12.028_b0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S1438-4221(02)80007-8","article-title":"Characterization of tick-borne encephalitis (TBE) foci in Germany and Latvia (1997\u20132000)","volume":"291","author":"S\u00fcss","year":"2002","journal-title":"Int J Med Microbiol: IJMM"},{"key":"10.1016\/j.vaccine.2021.12.028_b0095","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ttbdis.2018.02.007","article-title":"Self-reported tick-borne encephalitis (TBE) vaccination coverage in Europe: results from a cross-sectional study","volume":"9","author":"Erber","year":"2018","journal-title":"Ticks Tick Borne Dis"},{"issue":"1090","key":"10.1016\/j.vaccine.2021.12.028_b0100","first-page":"e7","article-title":"Tick-borne encephalitis virus vaccination breakthrough infections in Germany: a retrospective analysis from 2001 to 2018","volume":"26","author":"Dobler","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.12.028_b0105","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2007. Berlin; 2008."},{"key":"10.1016\/j.vaccine.2021.12.028_b0110","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2008. Berlin; 2009."},{"key":"10.1016\/j.vaccine.2021.12.028_b0115","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2009. Berlin; 2010."},{"key":"10.1016\/j.vaccine.2021.12.028_b0120","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2010. Berlin; 2011."},{"key":"10.1016\/j.vaccine.2021.12.028_b0125","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2011. Berlin; 2012."},{"key":"10.1016\/j.vaccine.2021.12.028_b0130","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2012. Berlin; 2013."},{"key":"10.1016\/j.vaccine.2021.12.028_b0135","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2013. Berlin; 2014."},{"key":"10.1016\/j.vaccine.2021.12.028_b0140","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2014. Berlin; 2015."},{"key":"10.1016\/j.vaccine.2021.12.028_b0145","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2015. Berlin; 2016."},{"key":"10.1016\/j.vaccine.2021.12.028_b0150","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2016. Berlin; 2017."},{"key":"10.1016\/j.vaccine.2021.12.028_b0155","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2017. Berlin; 2018."},{"key":"10.1016\/j.vaccine.2021.12.028_b0160","unstructured":"Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten f\u00fcr 2018. Berlin; 2019."},{"key":"10.1016\/j.vaccine.2021.12.028_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204844","article-title":"Tick-borne encephalitis: a 43-year summary of epidemiological and clinical data from Latvia (1973 to 2016)","volume":"13","author":"Zavadska","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.12.028_b0170","unstructured":"Pfizer. Summary of product characteristics - FSME-IMMUN. Available from: https:\/\/mri.cts-mrp.eu\/human\/downloads\/AT_H_0126_002_FinalSPC.pdf. Accessed Oct 1, 2021."},{"key":"10.1016\/j.vaccine.2021.12.028_b0175","series-title":"Categorical data analysis","author":"Agresti","year":"2013"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.12.028_b0180","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0264-410X(02)00813-7","article-title":"TBE vaccination and the Austrian experience","volume":"21","author":"Kunz","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.028_b0185","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1016\/j.vaccine.2010.02.001","article-title":"Vaccine failures after active immunisation against tick-borne encephalitis","volume":"28","author":"Andersson","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.028_b0190","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/cid\/ciz176","article-title":"Tick-borne encephalitis vaccine failures: a 10-year retrospective study supporting the rationale for adding an extra priming dose in individuals starting at age 50 years","volume":"70","author":"Hansson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.12.028_b0195","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.vaccine.2004.01.041","article-title":"Persistence of protective immunity following vaccination against tick-borne encephalitis\u2013longer than expected?","volume":"22","author":"Rendi-Wagner","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.028_b0200","article-title":"Tick-borne encephalitis in patients vaccinated against this disease","author":"Lotric-Furlan","year":"2017","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2021.12.028_b0205","unstructured":"Steffen RAE. Duration of protection by Tick-Borne Encephalitis (TBE) vaccines: opening a debate. In: Northern European Conference on Travel Medicine (NECTM). Stockholm; 2018."},{"key":"10.1016\/j.vaccine.2021.12.028_b0210","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.vaccine.2014.01.072","article-title":"Irregular tick-borne encephalitis vaccination schedules: the effect of a single catch-up vaccination with FSME-IMMUN. A prospective non-interventional study","volume":"32","author":"Schosser","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.028_b0215","doi-asserted-by":"crossref","unstructured":"Khan F, Wang X, Cai B, Erber W, Schmitt HJ. Letter to the editor: Readers response to Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules. Hum Vaccin Immunother 2020:1\u20132.","DOI":"10.1080\/21645515.2020.1783954"},{"key":"10.1016\/j.vaccine.2021.12.028_b0220","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1128\/JVI.02985-15","article-title":"Molecular basis of the divergent immunogenicity of two pediatric tick-borne encephalitis virus vaccines","volume":"90","author":"Beck","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.12.028_b0225","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.vaccine.2011.12.013","article-title":"Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes","volume":"30","author":"Fritz","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.028_b0230","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/infdis\/jir122","article-title":"A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans","volume":"203","author":"Orlinger","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.12.028_b0235","doi-asserted-by":"crossref","unstructured":"Lindqvist R, Rosendal E, Asghar N, Schreier S, Lenman A, Johansson M, et al. The envelope protein of tick-borne encephalitis virus influence neuron entry, pathogenicity and vaccine protection. Research Square; 2020.","DOI":"10.21203\/rs.3.rs-24796\/v1"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2101639X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2101639X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:06:57Z","timestamp":1759403217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2101639X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0264410X2101639X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of TBE vaccination in southern Germany and Latvia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}